Request Sample
Request Methodology
Description
Microbiome Therapeutics Market Size was valued at USD 321.58 million in 2021 and is estimated to reach 1338.82 million by 2028, at a CAGR of 22.6% during the forecast period 2022 to 2028. A microbiome is the genetic material of all microbes such as bacteria, viruses, fungi, and protozoa that live on and inside the human body. Every part of the body has different types of microbes. For instance, about a third of bacteria in the gut are Bacteroides species, whereas Streptococcus species are dominant in oral health. The market plays a significant role in human health and disease conditions. The global microbiome therapeutics market is still nascent stage, very few products in the market are currently approved to treat various therapeutic conditions. Start-ups are very active in terms of microbiome therapeutics market growth, product launches, research, and development activities. However, bigger players in the microbiome therapeutics market are focused to provide funding, collaborating, and acquiring smaller players to promote the research activities. Furthermore, Venture Capitalists and Government Organisations are actively involved in funding and encouraging research activities. The launch of microbiome therapeutics products in the market is expected to fuel the demand of the market over the forecast. For instance, in May 2014, Pfizer entered an agreement with Second Genome to conduct research on obesity and metabolic disorders. In April 2016, the company also raised US$ 42.6 Mn in Series B funding led by Pfizer Venture Investments and Roche Venture Fund. The funding amount will be used to conduct the clinical investigation on SGM-109, a small molecule inhibitor of a microbiome-mediated target to address inflammation and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US$ 40 Mn in Series B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for inborn errors of metabolism of Urea Cycle Disorder and Phenylketonuria conditions.
Key Developments:
In July 2016, Series Therapeutics started a clinical trial on its synthetically designed microbiome drug SER-262, to treat Clostridium difficile infection conditions. The study is currently enrolling patients from 22 locations in the U.S.
In February 2015, 4D Pharma plc, U.K. based company, acquired Tucana involved in the development of microbiome therapeutics products to treat Irritable Bowel Syndrome (IBS) conditions
In January 2016, Takeda Pharmaceuticals Ltd and Enterome entered a strategic drug discovery collaboration to conduct research and development on novel therapeutics that target the microbiome that plays crucial roles in multiple gastrointestinal disease conditions
